Get the Stockscreener App
198.61
0.17%
-0.33
Pre-market:
200.11
1.50
+0.76%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $198.61, with a volume of 792.37K.
It is down -0.17% in the last 24 hours and down -3.35% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$198.94
Open:
$200.7
24h Volume:
792.37K
Relative Volume:
0.81
Market Cap:
$21.82B
Revenue:
$11.04B
Net Income/Loss:
$1.04B
P/E Ratio:
22.67
EPS:
8.7626
Net Cash Flow:
$1.36B
1W Performance:
-1.14%
1M Performance:
-3.35%
6M Performance:
+8.98%
1Y Performance:
+14.49%
1-Day Range:
$197.18
$200.70
1-Week Range:
$197.18
$205.00
52-Week Range:
$157.20
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
198.61 | 21.86B | 11.04B | 1.04B | 1.36B | 8.7626 |
|
TMO
Thermo Fisher Scientific Inc
|
472.71 | 174.60B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
195.21 | 135.34B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
586.98 | 46.69B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
112.75 | 31.60B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
296.99 | 28.45B | 3.17B | 642.63M | 516.49M | 10.77 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Danica Pension Livsforsikringsaktieselskab Buys Shares of 70,846 Quest Diagnostics Incorporated $DGX - MarketBeat
4 Outpatient Home Health Stocks Gaining Attention Amid Market Shifts - TradingView
Quest Diagnostics Incorporated $DGX Shares Sold by Chevy Chase Trust Holdings LLC - MarketBeat
Quest Diagnostics (DGX) down 4.2% since last earnings report: Can it rebound? - MSN
Aquatic Capital Management LLC Has $8.06 Million Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
EdgePoint Investment Group Inc. Grows Position in Quest Diagnostics Incorporated $DGX - MarketBeat
CSM Advisors LLC Sells 20,078 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Crawford Investment Counsel Inc. Purchases 9,473 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Stock Position Increased by 8 Knots Management LLC - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Sees Large Decrease in Short Interest - MarketBeat
iSAM Funds UK Ltd Invests $1.47 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
Integral Health Asset Management LLC Sells 65,000 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Elects Wentworth to Board of Directors - New Jersey Business Magazine
Korea Investment CORP Sells 14,900 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Elects Former Walgreens Boots Alliance CEO Timothy Wentworth to Board of Directors - Minichart
Quest Diagnostics (DGX) Appoints Timothy Wentworth to Board of D - GuruFocus
Quest Diagnostics adds ex-Walgreens CEO to board - Investing.com South Africa
Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors - Quest Diagnostics Newsroom
Quest Diagnostics (DGX) Down 4.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Quest Diagnostics (DGX) director Timothy Wentworth files insider Form 3 - Stock Titan
Quest Diagnostics Incorporated $DGX Position Trimmed by Schroder Investment Management Group - MarketBeat
Quest Diagnostics Expands Preventive Reach With Shield Colorectal Blood Test - simplywall.st
First Trust Advisors LP Raises Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Banque Cantonale Vaudoise Acquires 5,985 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Should You Keep DGX Shares in Your Investment Portfolio? - Bitget
Should You Continue to Hold DGX Stock in Your Portfolio? - The Globe and Mail
Barclays PLC Has $47.86 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Plewman Patrick, Quest Diagnostics SVP, sells $588k in stock By Investing.com - Investing.com India
Implied volatility surging for Quest Diagnostics stock options - MSN
Insider Selling: Quest Diagnostics (NYSE:DGX) EVP Sells $1,146,115.18 in Stock - MarketBeat
Insider Selling: Quest Diagnostics (NYSE:DGX) SVP Sells 3,878 Shares of Stock - MarketBeat
Plewman Patrick, Quest Diagnostics SVP, sells $588k in stock - Investing.com Nigeria
Quest Diagnostics Insider Sold Shares Worth $799,682, According to a Recent SEC Filing - marketscreener.com
Quest Diagnostics (DGX) SVP awarded 5,682 shares; 2,326 withheld for taxes - Stock Titan
Quest Diagnostics (DGX) SVP & General Counsel reports award, tax withholding and 10b5-1 share sale - Stock Titan
Quest Diagnostics (DGX) CEO receives stock award and uses shares for taxes - Stock Titan
Quest Diagnostics (DGX) SVP granted 6,200 shares, surrenders 2,628 for taxes - Stock Titan
Dimensional Fund Advisors LP Has $363.51 Million Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Implied Volatility Surging for Quest Diagnostics Stock Options - TradingView
3,878-Share Rule 144 Notice for DGX (NYSE: DGX) Insider Sales - Stock Titan
Genomics Services Market Projected to Surpass USD 25.18 Billion by 2035; Increasing Genetic Disorders’ Prevalence is Driving Market Growth Globally – SNS Insider - GlobeNewswire Inc.
Elo Mutual Pension Insurance Co Makes New $2.03 Million Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (NYSE: DGX) EVP sells shares and disposes stock for taxes - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP sells 526 shares in plan - Stock Titan
Quest Diagnostics (NYSE: DGX) CEO discloses 10,000-share stock sale - Stock Titan
Quest Diagnostics (DGX) SVP sells and withholds shares under plan - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP covers tax obligations with share sale - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP reports tax-withholding stock disposition on Form 4 - Stock Titan
Quest Diagnostics Hits New 52-Week High of $213.50, Up 49.79% - Markets Mojo
Quest Diagnostics Remains a Dominant Competitor in Independent Labs - Morningstar
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):